- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07945431
A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction
A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction
This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Todd Bertoch, MD
- Telefonnummer: 928 830 7354
- E-mail: t.bertoch@cenexel.com
Undersøgelse Kontakt Backup
- Navn: CenExel JBR Recruiting
Studiesteder
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84107
- CenExel JBR Clinical Research
-
Kontakt:
- Todd M Burtoch, MD
- Telefonnummer: 2303 (801) 261-2000
- E-mail: t.bertoch@cenexel.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is male or female ≥ 18 and ≤ 50 years of age.
- Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
- Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
- Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2.
- Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (defined as no menses for 12 months without an alternative medical cause).
- Free of clinically significant abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
- Able to provide written informed consent.
- Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)
Exclusion Criteria:
- Known hypersensitivity or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
- History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or clinically significant baseline laboratory abnormalities at Screening, defined as serum ALT or AST > 1.5× the Upper Limit of Normal (ULN), or total bilirubin > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
- Complications from tooth extraction resulting in a "severe" surgical trauma rating.
- Dental surgery within 60 days prior to Day 1.
- Positive urine drug screen or alcohol breathalyzer test.
- Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
- Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
- Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ≥ 4 weeks prior to Screening.
- History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or glucocorticoids for any condition within 6 months prior to dosing.
- Difficulty swallowing oral medication.
- Investigational drug exposure within 30 days or 5 half-lives.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: SRP-001
SRP-001 Single Oral Suspension dose of 2,000 mg |
SRP-001 Oral Suspension |
|
Placebo komparator: Matching Placebo for SRP-001
Matching Placebo for SRP-001 Oral Suspension |
Matching Placebo for SRP-001 Oral Suspension
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
Tidsramme: 0 to 6 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo. |
0 to 6 hours post-dose
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
Tidsramme: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse) |
0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
|
Sum of pain relief (TOTPAR)
Tidsramme: O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose. |
O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
|
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
Tidsramme: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
Tidsramme: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to first use of rescue medication
Tidsramme: 0 - 6, 0-8, 0-24 hours post dose.
|
Rescue medication time for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Total rescue medication consumption
Tidsramme: 0 - 6, 0-8, 0-24 hours post dose.
|
Total rescue medication consumption for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication |
Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
|
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
Tidsramme: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
Pain intensity difference (PID) Scale is -10 to 10 (higher is better) |
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
|
Patient's global evaluation of study drug using a 5 point categorical scale
Tidsramme: Up to 6 hours post dose
|
Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent |
Up to 6 hours post dose
|
|
Number of participants with clinically significant abnormalities in laboratory abnormalities
Tidsramme: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
Number of participants with laboratory values judged clinically significant by the investigator in the following panels: Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential) |
Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
|
Maximum Observed Plasma Concentration (CMax) of SRP-001
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Time to maximum observed plasma concentration (Tmax) of SRP-001
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
Tidsramme: Pre-dose through 12 hours post-dose
|
AUC0-12 of SRP-001 following a single 2,000mg oral dose. |
Pre-dose through 12 hours post-dose
|
|
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-t of SRP001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-inf of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Terminal elimination half life (t 1/2) of SRP-001
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
t 1/2 of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent oral clearance (CL/F) of SRP-001
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CL/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Vz/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
Tidsramme: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Pain relief difference (PR) |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to first perceptible relief and time to confirmed perceptible pain relief
Tidsramme: 0-4.5 hours post dose
|
TPPR and TCPR via stopwatch 1 |
0-4.5 hours post dose
|
|
Time to meaningful relief
Tidsramme: 0-4.5 hours post dose
|
TMPR via Stopwatch 2 |
0-4.5 hours post dose
|
|
Time to complete pain relief
Tidsramme: 0 to 8 hours post-dose
|
TCOMPR, NPRS = 0 |
0 to 8 hours post-dose
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Todd M Bertoch, MD, CenExel JBR Clinical Research
Publikationer og nyttige links
Generelle publikationer
- Coderch C, Bazan HA, Bazan NG, Surjyadipta B, Alvarez-Builla J, de Pascual-Teresa B. Computational Insights into the Structural Basis for Reduced Hepatotoxicity of Novel Nonopioid Analgesics. ChemMedChem. 2025 Nov 18;20(22):e202500639. doi: 10.1002/cmdc.202500639. Epub 2025 Oct 21.
- Olson AC, Afyusisye F, Egger J, Noyd D, Likonda B, Masalu N, Suneja G, Chao N, Zullig LL, Schroeder K. Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases. Cancer Epidemiol. 2020 Aug;67:101772. doi: 10.1016/j.canep.2020.101772. Epub 2020 Jul 10.
- Bazan HA, Giles BL, Bhattacharjee S, Edwards S, Bazan NG. A non-toxic analgesic elicits cell-specific genomic and epigenomic modulation by targeting the PAG brain region. Neurobiol Pain. 2025 Jul 20;18:100192. doi: 10.1016/j.ynpai.2025.100192. eCollection 2025 Jul-Dec.
- Frelinger AL 3rd, Haynes RL, Goldstein RD, Berny-Lang MA, Gerrits AJ, Riehs M, Haas EA, Paunovic B, Mena OJ, Campman SC, Milne GL, Sleeper LA, Kinney HC, Michelson AD. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 May 15;14(1):11092. doi: 10.1038/s41598-024-61949-9.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SRP-001-002
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .